186 related articles for article (PubMed ID: 37814439)
1. Distinct Effects of Non-absorbed Agents Rifaximin and Berberine on the Microbiota-Gut-Brain Axis in Dysbiosis-induced Visceral Hypersensitivity in Rats.
Zhang J; Zhang C; Zhang T; Zhang L; Duan L
J Neurogastroenterol Motil; 2023 Oct; 29(4):520-531. PubMed ID: 37814439
[TBL] [Abstract][Full Text] [Related]
2. Berberine alleviates visceral hypersensitivity in rats by altering gut microbiome and suppressing spinal microglial activation.
Zhang JD; Liu J; Zhu SW; Fang Y; Wang B; Jia Q; Hao HF; Kao JY; He QH; Song LJ; Liu F; Zhu BL; Owyang C; Duan LP
Acta Pharmacol Sin; 2021 Nov; 42(11):1821-1833. PubMed ID: 33558654
[TBL] [Abstract][Full Text] [Related]
3. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.
Zhuang X; Tian Z; Li L; Zeng Z; Chen M; Xiong L
Front Microbiol; 2018; 9():1600. PubMed ID: 30090090
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y; Ren X; Li G; Li Y; Zhang L; Wang H; Qian W; Hou X
J Gastroenterol Hepatol; 2018 Feb; 33(2):443-452. PubMed ID: 28573746
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice.
Zhang S; Hong G; Li G; Qian W; Jin Y; Hou X
BMC Microbiol; 2023 Jan; 23(1):22. PubMed ID: 36658488
[TBL] [Abstract][Full Text] [Related]
6. Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially.
Jia Q; Zhang L; Zhang J; Pei F; Zhu S; Sun Q; Duan L
Biomed Res Int; 2019; 2019():4530203. PubMed ID: 31073525
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.
Ponziani FR; Pecere S; Lopetuso L; Scaldaferri F; Cammarota G; Gasbarrini A
Expert Opin Drug Saf; 2016 Jul; 15(7):983-91. PubMed ID: 27149541
[TBL] [Abstract][Full Text] [Related]
8. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
9. Intestinal Fungal Dysbiosis Is Associated With Visceral Hypersensitivity in Patients With Irritable Bowel Syndrome and Rats.
Botschuijver S; Roeselers G; Levin E; Jonkers DM; Welting O; Heinsbroek SEM; de Weerd HH; Boekhout T; Fornai M; Masclee AA; Schuren FHJ; de Jonge WJ; Seppen J; van den Wijngaard RM
Gastroenterology; 2017 Oct; 153(4):1026-1039. PubMed ID: 28624575
[TBL] [Abstract][Full Text] [Related]
10. Effect of altered gut microbiota on visceral hypersensitivity of postinfectious irritable bowel syndrome mice.
Cheng F; Fan Z; Lin C; Zhu Y; He H; Dai N; Du L
Eur J Gastroenterol Hepatol; 2022 Dec; 34(12):1220-1230. PubMed ID: 36165068
[TBL] [Abstract][Full Text] [Related]
11. Increased Expression of Colonic Mucosal Melatonin in Patients with Irritable Bowel Syndrome Correlated with Gut Dysbiosis.
Wang B; Zhu S; Liu Z; Wei H; Zhang L; He M; Pei F; Zhang J; Sun Q; Duan L
Genomics Proteomics Bioinformatics; 2020 Dec; 18(6):708-720. PubMed ID: 33607299
[TBL] [Abstract][Full Text] [Related]
12. [Effect of Gegen Qinlian Decoction on gut microbiota of irritable bowel syndrome with diarrhea rats].
Zhang RQ; Fang ZA; Han WQ; Jing JQ; Liu Y; Yu B; Wang R; Sun M
Zhongguo Zhong Yao Za Zhi; 2022 Dec; 47(24):6709-6719. PubMed ID: 36604921
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats.
Xu D; Gao J; Gillilland M; Wu X; Song I; Kao JY; Owyang C
Gastroenterology; 2014 Feb; 146(2):484-96.e4. PubMed ID: 24161699
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach.
Soldi S; Vasileiadis S; Uggeri F; Campanale M; Morelli L; Fogli MV; Calanni F; Grimaldi M; Gasbarrini A
Clin Exp Gastroenterol; 2015; 8():309-25. PubMed ID: 26673000
[TBL] [Abstract][Full Text] [Related]
15. Patients with breath test positive are necessary to be identified from irritable bowel syndrome: a clinical trial based on microbiomics and rifaximin sensitivity.
Liu Z; Zhu S; He M; Li M; Wei H; Zhang L; Sun Q; Jia Q; Hu N; Fang Y; Song L; Zhou C; Tao H; Kao JY; Zhu H; Owyang C; Duan L
Chin Med J (Engl); 2022 Jul; 135(14):1716-1727. PubMed ID: 36070467
[TBL] [Abstract][Full Text] [Related]
16. Electroacupuncture Relieves Irritable Bowel Syndrome by Regulating IL-18 and Gut Microbial Dysbiosis in a Trinitrobenzene Sulfonic Acid-Induced Post-Inflammatory Animal Model.
Song YF; Pei LX; Chen L; Geng H; Yuan MQ; Xu WL; Wu J; Zhou JY; Sun JH
Am J Chin Med; 2020; 48(1):77-90. PubMed ID: 31918565
[TBL] [Abstract][Full Text] [Related]
17. Irritable bowel syndrome and gut microbiota.
Canakis A; Haroon M; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):28-35. PubMed ID: 31789724
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota and therapeutic approaches for dysbiosis in irritable bowel syndrome: recent developments and future perspectives.
Dale HF; Lied GA
Turk J Med Sci; 2020 Nov; 50(SI-2):1632-1641. PubMed ID: 32222124
[TBL] [Abstract][Full Text] [Related]
19. Gut Microbiota Manipulation in Irritable Bowel Syndrome.
Mazzawi T
Microorganisms; 2022 Jun; 10(7):. PubMed ID: 35889051
[TBL] [Abstract][Full Text] [Related]
20. Sex-based differences in fecal short-chain fatty acid and gut microbiota in irritable bowel syndrome patients.
Sun QH; Liu ZJ; Zhang L; Wei H; Song LJ; Zhu SW; He MB; Duan LP
J Dig Dis; 2021 May; 22(5):246-255. PubMed ID: 33822477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
